Tumorigenesis and neurodegeneration: Two sides of the same coin?

BioEssays

Volumn 30, Issue 8, 2008, Pages 719-727

  Staropoli, John F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ATM PROTEIN; DNA; PARKIN;

ACUTE LEUKEMIA; ALZHEIMER DISEASE; APOPTOSIS; BREAST CANCER; CARCINOGENESIS; CELL CYCLE PROGRESSION; CEREBELLUM; DEGENERATIVE DISEASE; DEMENTIA; DNA REPAIR; DOWN REGULATION; DOWN SYNDROME; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC REGULATION; GENETIC SUSCEPTIBILITY; HEMATOLOGIC MALIGNANCY; HUMAN; MYELOPROLIFERATIVE DISORDER; NERVE CELL; NERVE CELL DEGENERATION; NONHUMAN; PARKINSON DISEASE; REVIEW; TUMOR SUPPRESSOR GENE;

AMYLOID; ANIMALS; BIOLOGICAL MARKERS; CELL CYCLE; CELL CYCLE PROTEINS; DNA REPAIR; DNA-BINDING PROTEINS; DOWN SYNDROME; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; NEURODEGENERATIVE DISEASES; NEURONS; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 48949100108     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.20784     Document Type: Review

References (90)

1. Deshpande A, Sicinski P, Hinds PW. 2005. Cyclins and cdks in development and cancer: a perspective. Oncogene 24:2909-2915.
2. Hershko A, Ciechanover A. 1998. The ubiquitin system. Annu Rev Biochem 67:425-479.
3. Michel JJ, Xiong Y. 1998. Human CUL-1, but not other cullin family members, selectively interacts with SKP1 to form a complex with SKP2 and cyclin A. Cell Growth Differ 9:435-449.
4. Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, et al. 2001. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 294:173-177.
5. Nateri AS, Riera-Sans L, Da Costa C, Behrens A. 2004. The ubiquitin ligase SCFFbw7 antagonizes apoptotic JNK signaling. Science 303: 1374-1378.
6. Staropoli JF, Abeliovich A. 2005. The ubiquitin-proteasome pathway is necessary for maintenance of the postmitotic status of neurons. J Mol Neurosci 27:175-183.
7. Bouman L. 1934. Senile plaques. Brain 57:128-142.
8. y Cajal R. 1928. Degeneration and regeneration of the nervous system. London: Oxford University Press.
9. Goldman SA, Sim F. 2005. Neural progenitor cells of the adult brain. Novartis Found Symp 265:66-80; discussion, 82-97.
10. Park DS, Morris EJ, Stefanis L, Troy CM, Shelanski ML, et al. 1998. Multiple pathways of neuronal death induced by DNA-damaging agents, NGF deprivation, and oxidative stress. J Neurosci 18:830-840.
11. Giardina SF, Beart PM. 2002. Kainate receptor-mediated apoptosis in primary cultures of cerebellar granule cells is attenuated by mitogen-activated protein and cyclin-dependent kinase inhibitors. Br J Pharmacol 135:1733-1742.
12. Verdaguer E, Garcia-Jorda E, Canudas AM, Dominguez E, Jimenez A, et al. 2002. Kainic acid-induced apoptosis in cerebellar granule neurons: an attempt at cell cycle re-entry. Neuroreport 13:413-416.
13. Kruman II. Wersto RP, Cardozo-Pelaez F, Smilenov L, Chan SL, et al. 2004. Cell cycle activation linked to neuronal cell death initiated by DNA damage. Neuron 41:549-561.
14. Yang Y, Geldmacher IDS, Herrup K. 2001. DNA replication precedes neuronal cell death in Alzheimer's disease. J Neurosci 21:2661-2668.
15. Feddersen RM, Ehlenfeldt R, Yunis WS, Clark HB, Orr HT. 1992. Disrupted cerebellar cortical development and progressive degeneration of Purkinje cells in SV40 T antigen transgenic mice. Neuron 9:955-966.
16. Klein JA, Longo-Guess CM, Rossmann MP, Seburn KL, Hurd RE, et al. 2002. The harlequin mouse mutation downregulates apoptosis-inducing factor. Nature 419:367-374.
17. Park IDS, Levine B, Ferrari G, Greene LA. 1997. Cyclin dependent kinase inhibitors and dominant negative cyclin dependent kinase 4 and 6 promote survival of NGF-deprived sympathetic neurons. J Neurosci 17:8975-8983.
18. Rideout HJ, Wang Q, Park DS, Stefanis L. 2003. Cyclin-dependent inase activity is required for apoptotic death but not inclusion formation n cortical neurons after proteasomal inhibition. J Neurosci 23:1237-1245.
19. Ackman JB, Ramos RL, Sarkisian MR, Loturco JJ. 2007. Citron kinase is required for postnatal neurogenesis in the hippocampus. Dev Neurosci 29:113-123.
20. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, et al. 2001. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21:3017-3023.
21. Raina AK, Zhu X, Rottkamp CA, Monteiro M, Takeda A, et al. 2000. Cyclin' toward dementia: cell cycle abnormalities and abortive oncogenesis in Alzheimer disease. J Neurosci Res 61:128-133.
22. Nouspikel T, Hanawalt PC. 2003. When parsimony backfires: neglecting DNA repair may doom neurons in Alzheimer's disease. Bioessays 25:168-173.
23. Lee Y, McKinnon PJ. 2007. Responding to DNA double strand breaks in the nervous system. Neuroscience 145:1365-1374.
24. Rolig RL, McKinnon PJ. 2000. Linking DNA damage and neurodegeneration. Trends Neurosci 23:417-424.
25. Eilam R, Peter Y, Groner Y, Segal M. 2003. Late degeneration of nigro-striatal neurons in ATM-/- mice. Neuroscience 121:83-98.
26. Eilam R, Peter Y, Elson A, Rotman G, Shiloh Y, et al. 1998. Selective loss of dopaminergic nigro-striatal neurons in brains of Atm-deficient mice. Proc Natl Acad Sci USA 95:12653-12656.
27. Gibb WR. 1986. Idiopathic Parkinson's disease and the Lewy body disorders. Neuropathol Appl Neurobiol 12:223-234.
28. Agamanolis DP, Greenstein JI. 1979. Ataxia-telangiectasia. Report of a case with Lewy bodies and vascular abnormalities within cerebral tissue. J Neuropathol Exp Neurol 38:475-489.
29. Thompson D, Duedal S, Kimer J, McGuffog L, Last J, et al. 2005. Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 97:813-822.
30. Elson A, Wang Y, Daugherty CJ, Morton CC, Zhou F, et al. 1996. Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc Natl Acad Sci USA 93:13084-13089.
31. Callen E, Jankovic M, Difilippantonio S, Daniel JA, Chen HT, et al. 2007. ATM prevents the persistence and propagation of chromosome breaks in lymphocytes. Cell 130:63-75.
32. Morrell D, Cromartie E, Swift M. 1986. Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. J Natl Cancer Inst 77:89-92.
33. Fegan C, Robinson H, Thompson P, Whittaker JA, White D. 1995. Karyotypic evolution in CLL: identification of a new sub-group of patients with defetions of 11q and advanced or progressive disease. Leukemia 9:2003-2008.
34. Hasle H, Clemmensen IH, Mikkelsen M. 2000. Risks of leukaemia and solid tumours in individuals with Down's syndrome. Lancet 355:165-169.
35. Vyas P, Crispino JD. 2007. Molecular insights into Down syndrome-associated leukemia. Curr Opin Pediatr 19:9-14.
36. Look AT. 2002. A leukemogenic twist for GATA1. Nat Genet 32:83-84.
37. Rainis L, Toki T, Pimanda JE, Rosenthal E, Machol K, et al. 2005. The proto-oncogene ERG in megakaryoblastic leukemias. Cancer Res 65: 7596-7602.
38. Steidl U, Kronenwett R, Rohr UP, Fenk R, Kliszewski S, et al. 2002. Gene expression profiling identifies significant differences between the molecular phenotypes of bone marrow-derived and circulating human CD34+ hematopoietic stem cells. Blood 99:2037-2044.
39. Baldus CD, Liyanarachchi S, Mrozek K, Auer H, Tanner SM, et al. 2004. Acute myeloid leukemia with complex karyotypes and abnormal chromosome 21: Amplification discloses overexpression of APP, ETS2, and ERG genes. Proc Natl Acad Sci USA 101:3915-3920.
40. Suram A, Venugopal C, Prakasam A, Sambamurti K. 2006. Genotoxicity in Alzheimer's disease: role of amyloid. Curr Alzheimer Res 3:365-375.
41. Jhanwar-Uniyal M. 2003. BRCA1 in cancer, cell cycle and genomic stability. Front Biosci 8:s1107-s1117.
42. Evans TA, Raina AK, Delacourte A, Aprelikova O, Lee HG, et al. 2007. BRCA1 may modulate neuronal cell cycle re-entry in Alzheimer disease. Int J Med Sci 4:140-145.
43. Zhu X, Raina AK, Boux H, Simmons ZL, Takeda A, et al. 2000. Activation of oncogenic pathways in degenerating neurons in Alzheimer disease. Int J Dev Neurosci 18:433-437.
44. Previll LA, Crosby ME, Castellani RJ, Bowser R, Perry G, et al. 2007. Increased expression of p130 in Alzheimer disease. Neurochem Res 32:639-644.
45. Woods J, Snape M, Smith MA. 2007. The cell cycle hypothesis of Alzheimer's disease: suggestions for drug development. Biochim Biophys Acta 1772:503-508.
46. Cimino M, Balduini W, Carloni S, Gelosa P, Guerrini U, et al. 2005. Neuroprotective effect of simvastatin in stroke: a comparison between adult and neonatal rat models of cerebral ischemia. Neurotoxicology 26:929-933.
47. Harvey BK, Shen H, Chen GJ, Yoshida Y, Wang Y. 2004. Midkine and retinoic acid reduce cerebral infarction induced by middle cerebral artery ligation in rats. Neurosci Lett 369:138-141.
48. Luo Y, Yin W, Signore AP, Zhang F, Hong Z, et al. 2006. Neuroprotection against focal ischemic brain injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. J Neurochem 97:435-448.
49. Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE. 2007. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 6:652-662.
50. Oliveira SA, Scott WK, Martin ER, Nance MA, Watts RL, et al. 2003. Parkin mutations and susceptibility alleles in late-onset Parkinson's disease. Ann Neurol 53:624-629.
51. Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, et al. 2002. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36:1007-1019.
52. Darios F, Corti O, Lucking CB, Hampe C, Muriel MP, et al. 2003. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Hum Mol Genet 12:517-526.
53. Staropoli JF, McDermott C, Martinat C, Schulman B, Demireva E, et al. 2003. Parkin is a component of an SCF-like ubiquitin ligase complex and protects postmitotic neurons from kainate excitotoxicity. Neuron 37:735-749.
54. Gill JS, Windebank AJ. 2000. Ceramide initiates NFkappaB-mediated caspase activation in neuronal apoptosis. Neurobiol Dis 7:448-461.
55. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC. 1999. Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 98: 859-869.
56. Nguyen MD, Mushynski WE, Julien JP. 2002. Cycling at the interface between neurodevelopment and neurodegeneration. Cell Death Differ 9:1294-1306.
57. Feany MB, Pallanck LJ. 2003. Parkin: a multipurpose neuroprotective agent? Neuron 38:13-16.
58. Kawakami K, Futami H, Takahara J, Yamaguchi K. 1996. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line. Biochem Biophys Res Commun 219:778-783.
59. Cesari R, Martin ES, Calin GA, Pentimalli F, Bichi R, et al. 2003. Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. Proc Natl Acad Sci USA 100:5956-5961.
60. Denison SR, Wang F, Becker NA, Schule B, Kock N, et al. 2003. Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene 22:8370-8378.
61. Wang F, Denison S, Lai JP, Philips LA, Montoya D, et al. 2004. Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer 40:85-96.
62. Picchio MC, Martin ES, Cesari R, Calin GA, Yendamuri S, et al. 2004. Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. Clin Cancer Res 10:2720-2724.
63. Agirre X, Roman-Gomez J, Vazquez I, Jimenez-Velasco A, Garate L, et al. 2006. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int J Cancer 118: 1945-1953.
64. Courjal F, Louason G, Speiser P, Katsaros D, Zeillinger R, et al. 1996. Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 69:247-253.
65. Sewing A, Ronicke V, Burger C, Funk M, Muller R. 1994. Alternative splicing of human cyclin E. J Cell Sci 107:581-588.
66. Mumberg D, Wick M, Burger C, Haas K, Funk M, et al. 1997. Cyclin ET, a new splice variant of human cyclin E with a unique expression pattern during cell cycle progression and differentiation. Nucleic Acids Res 25:2098-2105.
67. Donnellan R, Chetty R. 1999. Cyclin E in human cancers. Faseb J 13:773-780.
68. Spruck CH, Strohmaier H, Sangfelt O, Muller HM, Hubalek M, et al. 2002. hCDC4 gene mutations in endometrial cancer. Cancer Res 62:4535-4539.
69. Ekholm-Reed S, Spruck CH, Sangfelt O, van Drogen F, Mueller-Holzner E, et al. 2004. Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer. Cancer Res 64:795-800.
70. Moller H, Mellemkjaer L, McLaughlin JK, Olsen JH. 1995. Occurrence of different cancers in patients with Parkinson's disease. Bmj 310:1500-1501.
71. Olsen JH, Friis S, Frederiksen K, McLaughlin JK, Mellemkjaer L, et al. 2005. Atypical cancer pattern in patients with Parkinson's disease. Br J Cancer 92:201-205.
72. Unoki M, Nakamura Y. 2001. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20:4457-4465.
73. Matsushima-Nishiu M, Unoki M, Ono K, Tsunoda T, Minaguchi T, et al. 2001. Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN. Cancer Res 61:3741-3749.
74. Baker SJ, McKinnon PJ. 2004. Tumour-suppressor function in the nervous system. Nat Rev Cancer 4:184-196.
75. Crackower MA, Oudit GY, Kozieradzki I, Sarao R, Sun H, et al. 2002. Regulation of myocardial contractility and cell size by distinct P13K-PTEN signaling pathways. Cell 110:737-749.
76. Suzuki A, Itami S, Ohishi M, Hamada K, Inoue T, et al. 2003. Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation. Cancer Res 63:674-681.
77. Kwon CH, Luikart BW, Powell CM, Zhou J, Matheny SA, et al. 2006. Pten regulates neuronal arborization and social interaction in mice. Neuron 50:377-388.
78. Butler MG, Dasouki MJ, Zhou XP, Talebizadeh Z, Brown M, et al. 2005. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet 42:318-321.
79. Gallo KA, Johnson GL. 2002. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat Rev Mol Cell Biol 3:663-672.
80. Jeon SH, Kim YS, Bae CD, Park JB. 2000. Activation of JNK and p38 in rat hippocampus after kainic acid induced seizure. Exp Mol Med 32: 227-230.
81. Saporito MS, Thomas BA, Scott RW. 2000. MPTP activates c-Jun NH(2)-terminal kinase (JNK) and its upstream regulatory kinase MKK4 in nigrostriatal neurons in vivo. J Neurochem 75:1200-1208.
82. Willesen MG, Gammeltoft S, Vaudano E. 2002. Activation of the c-Jun N terminal kinase pathway in an animal model of Parkinson's disease. Ann N Y Acad Sci 973:237-240.
83. Ham J, Babij C, Whitfield J, Pfarr CM, Lallemand D, et al. 1995. A c-Jun dominant negative mutant protects sympathetic neurons against programmed cell death. Neuron 14:927-939.
84. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, et al. 1998. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell 1:543-551.
85. Whitfield J, Neame SJ, Paquet L, Bernard O, Ham J. 2001. Dominant-negative c-Jun promotes neuronal survival by reducing BIM expression and inhibiting mitochondrial cytochrome c release. Neuron 29:629-643.
86. Putcha GV, Le S, Frank S, Besirli CG, Clark K, et al. 2003. JNK-mediated BIM phosphorylation potentiates BAX-dependent apoptosis. Neuron 38: 899-914.
87. Yang DD, Kuan CY, Whitmarsh AJ, Rincon M, Zheng TS, et al. 1997. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene. Nature 389:865-870.
88. Xia XG, Harding T, Weller M, Bieneman A, Uney JB, et al. 2001. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc Natl Acad Sci USA 98: 10433-10438.
89. Investigators TPSGP. 2007. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 69:1480-1490.
90. Cha GH, Kim S, Park J, Lee E, Kim M, et al. 2005. Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. Proc Natl Acad Sci USA 102:10345-10350.